Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
A low-carbohydrate diet is effective to improve hyperglycemia via insulin-independent actions. We report here that a low-carbohydrate diet combined with an SGLT2 inhibitor was effective and safe to treat refractory hyperglycemia in the perioperative period in a type 2 diabetes patient complicated with a high titer of insulin antibodies.
Department of Endocrinology and Metabolism, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Electronic address: a205mm038s@yahoo.co.jp.
Riyoko
R
Shigeno
Department of Endocrinology and Metabolism, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Electronic address: holy197741@me.com.
Ichiro
I
Horie
Department of Endocrinology and Metabolism, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Electronic address: takaoando@gmail.com.
Takao
T
Ando
Department of Endocrinology and Metabolism, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Electronic address: abirun@nagasaki-u.ac.jp.
Norio
N
Abiru
Department of Endocrinology and Metabolism, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Electronic address: atsushik@nagasaki-u.ac.jp.
Atsushi
A
Kawakami
D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D000368:Aged; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology / Q000628:therapy*; D050528:Diet, Carbohydrate-Restricted / Q000379:methods*; D004359:Drug Therapy, Combination; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007330:Insulin Antibodies / Q000276:immunology; D007333:Insulin Resistance / Q000276:immunology*; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D009570:Nitriles / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000077597:Vildagliptin
D001559:Benzhydryl Compounds; D001786:Blood Glucose; D002096:C-Peptide; D005960:Glucosides; D007004:Hypoglycemic Agents; D007328:Insulin; D007330:Insulin Antibodies; D009570:Nitriles; D011759:Pyrrolidines; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin; D008687:Metformin; D000077597:Vildagliptin; D000218:Adamantane
Insulin antibodies; Insulin autoimmune syndrome; Low-carbohydrate diet; SGLT2; Scatchard analysis